- Home
- QTTB vs APVO Comparison
QTTB vs APVO Comparison
Compare QTTB & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- APVO
- Stock Information
- Founded
- QTTB 2015
- APVO 2016
- Country
- QTTB United States
- APVO United States
- Employees
- QTTB N/A
- APVO N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- QTTB Health Care
- APVO Health Care
- Exchange
- QTTB Nasdaq
- APVO Nasdaq
- Market Cap
- QTTB 26.3M
- APVO 21.7M
- IPO Year
- QTTB N/A
- APVO N/A
- Fundamental
- Price
- QTTB $2.01
- APVO $1.11
- Analyst Decision
- QTTB Hold
- APVO
- Analyst Count
- QTTB 7
- APVO 0
- Target Price
- QTTB $12.17
- APVO N/A
- AVG Volume (30 Days)
- QTTB 81.9K
- APVO 757.6K
- Earning Date
- QTTB 11-13-2025
- APVO 11-06-2025
- Dividend Yield
- QTTB N/A
- APVO N/A
- EPS Growth
- QTTB N/A
- APVO N/A
- EPS
- QTTB N/A
- APVO N/A
- Revenue
- QTTB N/A
- APVO N/A
- Revenue This Year
- QTTB N/A
- APVO N/A
- Revenue Next Year
- QTTB N/A
- APVO N/A
- P/E Ratio
- QTTB N/A
- APVO N/A
- Revenue Growth
- QTTB N/A
- APVO N/A
- 52 Week Low
- QTTB $1.35
- APVO $1.04
- 52 Week High
- QTTB $28.66
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- QTTB 38.52
- APVO 30.31
- Support Level
- QTTB $1.91
- APVO $1.39
- Resistance Level
- QTTB $2.42
- APVO $1.54
- Average True Range (ATR)
- QTTB 0.22
- APVO 0.09
- MACD
- QTTB -0.06
- APVO -0.03
- Stochastic Oscillator
- QTTB 13.66
- APVO 13.48
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.